BDSI actively seeks partnerships and product licenses in the areas of neurology, pain, psychiatry, and select rare diseases. We collaborate in ways that expand and strengthen the process of commercializing innovative therapies, and are open to working within a variety of mutually beneficial deal structures.
For more information on the growing BDSI portfolio, or to explore partnership opportunities, please contact Kevin Ostrander.
Kevin Ostrander, SVP, Business Development 4131 Parklake Avenue, Suite 225 Raleigh, NC 27612 Tel: 919-582-9050
New Scientific Information Further Highlights Differentiated Clinical Profile of BELBUCA® (buprenorphine buccal film) RALEIGH, N.C. , Sept. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patientsRead more
RALEIGH, N.C. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Interim Chief ExecutiveRead more
Second Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 Million Second Quarter BELBUCA® Net Sales Increased 34% versus Prior Year to $32.3 Million BELBUCA and Symproic® Each Reach All Time High TRx Volume and Market Share Conference Call and Webcast Scheduled for 8:30 AMRead more